Randomised Study of First TIME Immunotolerance Induction in Patients With Severe Type A Haemophilia With Inhibitor at High Risk of Failure: Comparison of Induction of Immune Tolerance With FVIII Concentrates With or Without Von Willebrand Factor Acronym: RES.I.S.T.- Naive
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 主要终点
- Primary end point is the success in inducing immune tolerance, defined as: the abolition of the inhibitor to < 0.6 BU within 33 months of ITI with a factor VIII recovery ≥ 66% and half-life ≥ 6 hrs, and measured after a 72-hour washout period.
研究概览
简要总结
This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
详细描述
The presence of Factor VIII (FVIII) inhibitor prevents FVIII infusions from working properly and makes treatment of bleeding episodes very difficult. Having an inhibitor is a serious and life-threatening complication in patients with Hemophilia. The usual treatment of patients with FVIII inhibitors involves "immune tolerance induction" (ITI). Immune Tolerance means that the body can accept infused FVIII and that FVIII is again effective in controlling bleeds. ITI involves giving high doses of FVIII regularly until the inhibitor disappears. This treatment is not always effective. The inhibitor persists in about 1 in 5 patients who undergo ITI.
There are 2 types of FVIII concentrates: FVIII concentrates derived from human plasma, which contain the von Willebrand factor, and concentrates of FVIII without VWF (recombinant or plasma derived). Both types of concentrates are commonly used to induce immune tolerance in patients with Hemophilia A. Retrospective studies in subjects with hemophilia and inhibitors at risk for failing ITI, have indicated a higher rate of success if patients were treated with von Willebrand containing factor VIII concentrates. It is not known whether the addition of Von Willebrand factor offers an advantage to achieving immune tolerance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •severe hemophilia A (FVIII<1%);
- •male, any age;
- •high responders (peak inhibitor levels > 5 BU);
- •any inhibitor level at study enrolment;
- •ability and willingness to participate in the study;
- •at least one of the following risk factors for ITI failure:
- •peak inhibitor titer > 200 BU
- •titer at ITI start > 10 BU
- •age > 7 years
- •time between inhibitor occurrence and ITI > 2 years
- •absence of high risk of cardiovascular, cerebrovascular or other thromboembolic events as deemed by the treating clinician.
排除标准
- •concomitant systemic treatment with immunosuppressive drugs;
- •concomitant experimental treatment;
- •previous ITI attempt;
- •previous history of myocardial infarction and/or cerebral stroke.
研究组 & 干预措施
von Willebrand factor-free FVIII concentrates
Patients treated with FVIII concentrates
干预措施: FVIII Concentrates (Drug)
FVIII/VWF concentrates
Patients treated with FVIII/VWF concentrates
干预措施: FVIII/VWF concentrates (Drug)
结局指标
主要结局
Primary end point is the success in inducing immune tolerance, defined as: the abolition of the inhibitor to < 0.6 BU within 33 months of ITI with a factor VIII recovery ≥ 66% and half-life ≥ 6 hrs, and measured after a 72-hour washout period.
时间窗: 33 months
次要结局
- Absence of relapse, up to 12 months after achievement of Immune Tolerance(12 months)
- Cost of Care(12 months)
- Time to achieve partial or complete success as defined in the protocol.(33 months)
- Safety Compliance to treatment(33 months)